2025-04-16 – Press Releases – www.prnewswire.com
MELBOURNE, Australia and INDIANAPOLIS, April 16, 2025 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces preliminary results from the Phase 2 IPAX-Linz study of TLX101 (131I-iodofalan[1]) in recurrent high-grade glioma (brain cancer),…